FBB
ABBV icon

Fulton Breakefield Broenniman’s AbbVie ABBV Stock Holding History

Fulton Breakefield Broenniman’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1M Sell
83,033
-1,663
-2% -$369K 1.18% 24
2025
Q4 		$19.4M Sell
84,696
-1,703
-2% -$388K 1.22% 22
2025
Q3 		$20M Sell
86,399
-552
-0.6% -$112K 1.29% 22
2025
Q2 		$16.1M Buy
86,951
+289
+0.3% +$53.7K 1.09% 27
2025
Q1 		$18.2M Sell
86,662
-3,049
-3% -$593K 1.31% 22
2024
Q4 		$15.9M Sell
89,711
-1,053
-1% -$194K 1.14% 28
2024
Q3 		$17.9M Sell
90,764
-3,730
-4% -$696K 1.25% 24
2024
Q2 		$16.2M Sell
94,494
-1,259
-1% -$209K 1.2% 27
2024
Q1 		$17.4M Sell
95,753
-1,250
-1% -$215K 1.34% 26
2023
Q4 		$15M Sell
97,003
-541
-0.6% -$78.9K 1.21% 34
2023
Q3 		$14.5M Buy
97,544
+586
+0.6% +$86K 1.26% 29
2023
Q2 		$13.1M Buy
96,958
+2,308
+2% +$338K 1.08% 40
2023
Q1 		$15.1M Buy
94,650
+1,168
+1% +$179K 1.3% 33
2022
Q4 		$15.1M Buy
93,482
+2,174
+2% +$333K 1.34% 33
2022
Q3 		$12.3M Sell
91,308
-282
-0.3% -$40.5K 1.15% 37
2022
Q2 		$14M Sell
91,590
-1,003
-1% -$153K 1.21% 36
2022
Q1 		$15M Buy
92,593
+17,785
+24% +$2.58M 1.32% 31
2021
Q4 		$10.1M Sell
74,808
-664
-0.9% -$78.4K 0.75% 51
2021
Q3 		$8.14M Buy
75,472
+109
+0.1% +$12.5K 0.7% 52
2021
Q2 		$8.49M Buy
75,363
+1,806
+2% +$203K 0.73% 51
2021
Q1 		$7.96M Buy
73,557
+12,007
+20% +$1.28M 0.74% 53
2020
Q4 		$6.59M Buy
61,550
+57,414
+1,388% +$5.52M 0.79% 52
2020
Q3 		$362K Hold
4,136
– – 0.04% 133
2020
Q2 		$406K Sell
4,136
-329
-7% -$29K 0.05% 123
2020
Q1 		$340K Sell
4,465
-663
-13% -$56.5K 0.05% 115
2019
Q4 		$454K Buy
5,128
+689
+16% +$57.2K 0.05% 123
2019
Q3 		$336K Buy
+4,439
New +$304K 0.04% 129

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fulton Breakefield Broenniman's ABBV Position: Q1 2026 in Review

Fulton Breakefield Broenniman reduced its AbbVie (ABBV) stake by 2% in Q1 2026, selling an estimated $369K and leaving 83,033 shares worth $18.1M. The position accounts for 1.18% of the portfolio, ranked #24.

Fulton Breakefield Broenniman first reported a position in ABBV in Q3 2019 and has held it in 27 quarters since. The position peaked at $20M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fulton Breakefield Broenniman held 83,033 shares of AbbVie worth $18.1M as of Q1 2026.
  • Fulton Breakefield Broenniman sold 1,663 AbbVie shares in Q1 2026, an estimated $369K.
  • AbbVie made up 1.18% of Fulton Breakefield Broenniman's portfolio in Q1 2026, its #24 holding.
  • Fulton Breakefield Broenniman first reported a position in AbbVie in Q3 2019 and has held it in 27 quarters since.
  • Fulton Breakefield Broenniman's AbbVie position peaked at $20M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fulton Breakefield Broenniman's 13F filing for Q1 2026, filed 27 Apr 2026.